Pipeline

Pipeline

Product CandidateIndicationPreclinicalEarly-Stage ClinicalLate-Stage Clinical
Nana-val (nanatinostat + valganciclovir)
 Relapsed/Refractory EBV+ Lymphoma

Nana-val
 Recurrent/Metastatic EBV+ Solid Tumors

Vecabrutinib BTK/ITK inhibitor, in combination w/ CAR T-cell therapy
 I-O Combinations Multiple Undisclosed

VRx-510* PDK-1 inhibitor
 Oncology
Multiple Undisclosed

Other HDACi Combinations
 HPV+ cancers
I-O Combinations Multiple Undisclosed

Product CandidateIndicationStage
Nana-val (nanatinostat + valganciclovir) Relapsed/Refractory EBV+ Lymphoma Late-Stage Clinical

Nana-val Recurrent/Metastatic EBV+ Solid Tumors Early-Stage Clinical

Vecabrutinib BTK/ITK inhibitor, in combination w/ CAR T-cell therapy I-O Combinations Multiple Undisclosed Early-Stage Clinical

VRx-510* PDK-1 inhibitor Oncology
Multiple Undisclosed		 Preclinical

Other HDACi Combinations HPV+ cancers
I-O Combinations Multiple Undisclosed		 Preclinical

EBV+: Epstein-Barr Virus Positive; I-O: Immuno-oncology; HPV: Human papillomavirus; *formerly SNS-510

Regulatory Status

The U.S. Food and Drug Administration (FDA) has granted Nana-val Fast Track Designation for the treatment of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoid malignancies, as well as Orphan Drug Designations for the treatment of:

  • T-cell lymphoma
  • Post-transplant lymphoproliferative disorder (PTLD)
  • Plasmablastic lymphoma
  • EBV+ diffuse large B-cell lymphoma, not otherwise specified

In addition, the European Commission has granted Nana-val Orphan Drug Designation for the treatment of diffuse large B-cell lymphoma and peripheral T-cell lymphoma.

Viracta is enrolling patients in clinical trials evaluating Nana-val as a treatment for relapsed/refractory EBV+ lymphomas as well as recurrent/metastatic EBV+ solid tumors. For more information about these studies, see ClinicalTrials.gov. identifiers NCT05011058 and NCT05166577, respectively.

Contact: clinicaltrials@viracta.com

Viracta has an Expanded Access Policy in compliance with the 21st Century Cures Act.